Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure

Circulation

Volumn 112, Issue 1, 2005, Pages 48-53

  Yusuf, Salim ^a,i   Ostergren, Jan B ^b   Gerstein, Hertzel C ^a   Pfeffer, Marc A ^c   Swedberg, Karl ^d   Granger, Christopher B ^e   Olofsson, Bertil ^f   Probstfield, Jeffrey ^g   McMurray, John V ^h  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f ASTRAZENECA R AND D   (Sweden)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ McMaster Clinic   (Canada)

Author keywords

Diabetes mellitus; Glucose; Heart failure; Prevention; Renin

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; NATEGLINIDE; PLACEBO; RAMIPRIL; TELMISARTAN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; GENETIC HETEROGENEITY; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 21844434198     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.528166     Document Type: Article

References (28)

1. King H, Aubert RE, Herman WH. Global burden of diabetes. 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998; 21:1414-1431.
2. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
3. Tuomilehto J, Lindstrom J, Eriksson JG. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
4. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359: 2072-2077.
5. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B: HOPE Study Investigators. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
7. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107:1291-1296.
8. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
9. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
10. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet. 2003;362:759-766.
11. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet. 2003;362:767-771.
12. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet. 2003;362:772-776.
13. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARM-Preserved trial. Lancet. 2003;362:777-781.
14. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension. 2002;40:609-611.
15. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens. 2002;20:965-973.
16. Furuhashi M, Iira N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003;42:76-81.
17. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia. 1999;42:128-138.
18. Schupp M, Janke J, Clasen R, Unger T, Kintscher U Angiotensin type I receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation. 2004;109:2054-2057.
19. DREAM Trial Investigators. Rationale, design and recruitment characteristics for a large simple international trial of diabetes prevention: the DREAM trial (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medications). Diabetologia. 2004;47:1519-1527.
20. Nateglinide and valsartan in impaired glucose tolerance outcomes research: rationale and design of the NAVIGATOR trial. Diabetes 2002; 51(suppl 2):A116. Abstract.
21. The ONTARGET/TRANSCEND Investigators. Rationale, design and baseline characteristics of two large, simple randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ONTARGET/TRANSCEND trials. Am Heart J. 2004;148:52-61.
22. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361: 1843-1848.
23. HOPE and HOPE-TOO Investigators. Long-term effects of ramipril on cardiovascular events and diabetes: results of the HOPE Study Evaluation. Circulation. In press.
24. McMurray JJ, Ostergren J, Olofsson B, Granger CB, Michelson E, Young JB, Dunlap M, Yusuf S, Swedberg K, Pfeffer MA, for the CHARM Investigators. Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: results of the candesartan in heart failure-assessment of reduction in mortality and morbidity programme (CHARM). J Am Coll Cardiol. 2004;43(suppl A):206A. Abstract.
25. Swedberg K, Cohen-Solal A, Granger C, McMurray J, Olsson L, Pfeffer M, Yusuf S, Ostergren J. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: results from CHARM. J Am Coll Cardiol 2004;43(suppl A):222A. Abstract.
26. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
27. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21: 875-886.
28. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563-1574.